PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34733993-13	2021	CALD1-mediated PD-L1 overexpression (OE) was via the activation of the JAK/STAT signaling pathway; this effect was blocked by the specific JAK inhibitor Ruxolitinib.	ruxolitinib	153-164	CD274 molecule	Homo sapiens	15-20	
33341940-0	2021	Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma.	ruxolitinib	0-11	CD274 molecule	Homo sapiens	55-85	
35151642-4	2022	ATRA enhanced PD-L1 expression through increasing its protein stability and protein synthesis, which was suppressed by JAK pan-inhibitor ruxolitinib (RUX), but was enhanced by the combination with IFN-gamma.	ruxolitinib	137-148	CD274 molecule	Homo sapiens	14-19	
35151642-4	2022	ATRA enhanced PD-L1 expression through increasing its protein stability and protein synthesis, which was suppressed by JAK pan-inhibitor ruxolitinib (RUX), but was enhanced by the combination with IFN-gamma.	ruxolitinib	150-153	CD274 molecule	Homo sapiens	14-19	
34422627-7	2021	Recombinant human CXCL10 induced JAK-STAT and PD-L1, while the CXCL10-CXCR3 and JAK-STAT inhibitors AMG487 or ruxolitinib reduced the expression of PD-L1 in HFF-1 cells.	ruxolitinib	110-121	CD274 molecule	Homo sapiens	148-153	
33965175-12	2021	IFNgamma-induced immunosuppressive molecules IDO and PDL-1 were also inhibited by ruxolitinib on MSCs.	ruxolitinib	82-93	CD274 molecule	Homo sapiens	53-58	
33341940-0	2021	Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma.	ruxolitinib	0-11	CD274 molecule	Homo sapiens	87-92	
33341940-7	2021	Furthermore, RUX treatment resulted in a concentration-dependent reduction of PD-L1 gene expression in the MM tumour cells cultured alone or co-cultured with stromal cells compared with untreated cells.	ruxolitinib	13-16	CD274 molecule	Homo sapiens	78-83	
29933930-10	2018	In TNBC cell lines with 9p24.1 gain or amplification, PD-L1 expression rapidly and strikingly increased 5- to 38-fold with interferon-gamma (P < .05), and inducible PD-L1 expression was completely blocked by JAK2 knockdown and the JAK1/2 inhibitor ruxolitinib.	ruxolitinib	251-262	CD274 molecule	Homo sapiens	54-59	
31867003-6	2019	Using the HSG cell line, our results showed that both ICAM-1 and PD-L1 are induced by ROS through pSTAT3, and that this activation pathway is reversed by the use of JAK inhibitors, AG490 and ruxolitinib, as well as by N-acetylcysteine, which is a direct inhibitor of ROS.	ruxolitinib	191-202	CD274 molecule	Homo sapiens	65-70	
30035369-9	2018	Moreover, STAT1 knockdown significantly reduced EGF-mediated PD-L1 expression, and ruxolitinib, a JAK1/JAK2 inhibitor, significantly inhibited STAT1 phosphorylation to reduce the IFNr-mediated PD-L1 axis.	ruxolitinib	83-94	CD274 molecule	Homo sapiens	193-198	
29933930-10	2018	In TNBC cell lines with 9p24.1 gain or amplification, PD-L1 expression rapidly and strikingly increased 5- to 38-fold with interferon-gamma (P < .05), and inducible PD-L1 expression was completely blocked by JAK2 knockdown and the JAK1/2 inhibitor ruxolitinib.	ruxolitinib	251-262	CD274 molecule	Homo sapiens	168-173